Michael J. Haller
A5052802925- Diabetes Management and Research
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Diabetes Treatment and Management
- Diabetes Management and Education
- Diet, Metabolism, and Disease
- Immune Cell Function and Interaction
- Adolescent and Pediatric Healthcare
- Liver Disease Diagnosis and Treatment
- Diet and metabolism studies
- T-cell and B-cell Immunology
- Cardiovascular Function and Risk Factors
- Childhood Cancer Survivors' Quality of Life
- Cardiovascular Health and Disease Prevention
- Chronic Disease Management Strategies
- Mobile Health and mHealth Applications
- Primary Care and Health Outcomes
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Thyroid Disorders and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Celiac Disease Research and Management
- Digestive system and related health
- Growth Hormone and Insulin-like Growth Factors
- Media Studies and Communication
- Child and Adolescent Health
University of Florida
2016-2025
Florida College
2011-2025
University of Florida Health
2024
University of Fort Lauderdale
2024
InGen (France)
2024
University of Bristol
2023
Pacific Northwest Diabetes Research Institute
2022
Stanford Health Care
2022
Children's Hospital of Philadelphia
2020
St. Francis Xavier University
2013
Significance We describe a blood test for detection of cell death in specific tissues based on two principles: ( i ) dying cells release fragmented DNA to the circulation, and ii each type has unique methylation pattern. have identified tissue-specific markers developed method sensitive these plasma or serum. demonstrate utility identification pancreatic β-cell 1 diabetes, oligodendrocyte relapsing multiple sclerosis, brain patients after traumatic ischemic damage, exocrine pancreas cancer...
Despite substantial evidence of the benefit frequent self-monitoring blood glucose (SMBG) in type 1 diabetes, certain insurers limit number test strips that they will provide. The large database T1D Exchange clinic registry provided an opportunity to evaluate relationship between SMBG measurements per day and HbA1c levels across a wide age range children adults.The analysis included 20,555 participants with diabetes ≥1 year not using continuous monitor (11,641 younger than 18 years 8,914 old...
OBJECTIVE It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion a large cohort at varying ages diagnosis diabetes duration unknown. RESEARCH DESIGN AND METHODS was determined by measurement nonfasting serum C-peptide concentration 919 according to prespecified groups based on age disease (from 3 81 years' duration)....
Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab a human monoclonal antibody specific for tumor necrosis factor α that has already been approved the treatment several conditions in adults and children. Whether golimumab could preserve beta-cell function youth with newly diagnosed overt (stage 3) type unknown.In this phase 2, multicenter, placebo-controlled, double-blind, parallel-group trial, we randomly assigned, 2:1 ratio,...
OBJECTIVE Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of diabetes from normal glucose tolerance (NGT) to abnormal (AGT) and the effects treatment on immune metabolic responses. RESEARCH DESIGN AND METHODS conducted a phase 2, randomized, placebo-controlled, double-masked trial antibody-positive participants NGT who received...
Regulatory T-cells (Tregs) play a critical role in maintaining dominant peripheral tolerance. Previous characterizations of Tregs type 1 diabetes have used antibodies against CD4 and alpha-chain the interleukin-2 receptor complex (CD25). This report extends those investigations by addition more lineage-specific marker for Tregs, transcription factor forkhead box P3 (FOXP3), subjects with diabetes, their first-degree relatives, healthy control subjects. With inclusion this marker, two...
Young children have an unacceptably high prevalence of diabetic ketoacidosis (DKA) at the clinical diagnosis type 1 diabetes. The aim this study was to determine whether knowledge genetic risk and close follow-up for development islet autoantibodies through participation in Environmental Determinants Diabetes (TEDDY) results lower DKA diabetes onset aged <2 <5 years compared with population-based incidence studies registries.
Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.To assess efficacy and safety as an adjunct to insulin treating overweight diabetes.Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 aged 12.1 19.6 years (mean [SD] 15.3 [1.7] years) mean duration 7.0 (3.3) years, body mass index (BMI) 94th (4) percentile, total daily 1.1 (0.2)...
Previous efforts to preserve β cell function in individuals with type 1 diabetes (T1D) have focused largely on the use of single immunomodulatory agents administered within 100 days diagnosis. Based human and preclinical studies, we hypothesized that a combination low-dose anti-thymocyte globulin (ATG) pegylated granulocyte CSF (G-CSF) would patients established T1D (duration >4 months <2 years).A randomized, single-blinded, placebo-controlled trial was performed 25 subjects: 17 subjects...
OBJECTIVE A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized 1) ATG/GCSF or 2) ATG alone would slow the decline of β-cell function patients new-onset T1D &lt;100 days). RESEARCH DESIGN AND METHODS three-arm, randomized, double-masked, placebo-controlled trial was performed by Type...
Previous studies have noted a specific association between type 1 diabetes and insufficient levels of vitamin D, as well polymorphisms within genes related to D pathways. Here, we examined whether serum or genotypes the D-binding protein (VDBP), molecule key biologic actions specifically associate with disorder.A retrospective, cross-sectional analysis VDBP used samples from 472 individuals similar age sex distribution, including 153 control subjects, 203 patients diabetes, 116 first-degree...
OBJECTIVE Treatment of severe hypoglycemia with loss consciousness or seizure outside the hospital setting is presently limited to intramuscular glucagon requiring reconstitution immediately prior injection, a process prone error omission. A needle-free intranasal preparation was compared for treatment insulin-induced hypoglycemia. RESEARCH DESIGN AND METHODS At eight clinical centers, randomized crossover noninferiority trial conducted involving 75 adults type 1 diabetes (mean age, 33 ± 12...
Optimizing glycemic control in pediatric type 1 diabetes (T1D) is essential to minimizing long-term risk of complications. We used the T1D Exchange database from 58 US clinics identify differences management characteristics among children categorized as having excellent vs. poor control.
A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA1c for year in new-onset type diabetes. Subjects (N = 89) were randomized to 1) ATG pegylated granulocyte colony-stimulating factor (GCSF), 2) alone, or 3) placebo. Herein, we report 2-year area under curve (AUC) C-peptide HbA1c, prespecified...
OBJECTIVE Assessment of the predictive power The Environmental Determinants Diabetes in Young (TEDDY)-identified risk factors for islet autoimmunity (IA), type autoantibody appearing first, and 1 diabetes (T1D). RESEARCH DESIGN AND METHODS A total 7,777 children were followed from birth to a median 9.1 years age development autoantibodies progression T1D. Time-dependent sensitivity, specificity, receiver operating characteristic (ROC) curves calculated provide estimates their individual...
We examined the association between plasma 25-hydroxyvitamin D [25(OH)D] concentration and islet autoimmunity (IA) whether vitamin gene polymorphisms modify effect of 25(OH)D on IA risk. followed 8,676 children at increased genetic risk type 1 diabetes six sites in U.S. Europe. defined as positivity for least one autoantibody (GADA, IAA, or IA-2A) two more visits. conducted a set sampled nested case-control study 376 case subjects up to 3 control per subject. was measured all samples prior...
Pancreas size is reduced in patients at type 1 diabetes onset and autoantibody (AAB)-positive donors without diabetes. We sought to determine whether pancreas volume (PV) imaging could improve understanding of the loss first-degree relatives (FDRs) with also examined relationships among PV, AAB status, endocrine exocrine functions.We conducted a cross-sectional study that included five groups: AAB- control subjects (no no first- or second-degree diabetes) (N = 49), FDRs 61), AAB+ 67 total: n...